Testicular Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Testicular Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global testicular cancer market. The report identifies the key trends shaping and driving the global testicular cancer market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global testicular cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates that the global testicular cancer therapeutics market was valued at $91m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 3.8% over the next seven years, to reach $118m by 2017. The gradual growth of the market is primarily attributed to the expected continued domination of generics in the testicular cancer therapeutics market, as no disease-modifying molecule is expected to launch during the forecast period of 2017.
Scope
The report provides information on the key drivers and challenges of the testicular cancer therapeutics market. Its scope includes -
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
Summary
GlobalData, the industry analysis specialist, has released its new report, “Testicular Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global testicular cancer market. The report identifies the key trends shaping and driving the global testicular cancer market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global testicular cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates that the global testicular cancer therapeutics market was valued at $91m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 3.8% over the next seven years, to reach $118m by 2017. The gradual growth of the market is primarily attributed to the expected continued domination of generics in the testicular cancer therapeutics market, as no disease-modifying molecule is expected to launch during the forecast period of 2017.
Scope
The report provides information on the key drivers and challenges of the testicular cancer therapeutics market. Its scope includes -
- Annualized global testicular cancer therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. No molecules are present in Phase III stage of clinical trial.Two molecules are present in Phase II and one is in Phase I. Two molecules are first-in-class and one is me-too. The first-in-class molecules come under the category of cyclin-dependent kinase inhibitors, and the me-too molecule has DNA alkylating activity. The participation of companies in clinical trials for testicular cancer therapeutics is not significant
- Analysis of the current and future competition in the global testicular cancer therapeutics market. The competition in the testicular cancer therapeutics market is weak. The market is dominated by generics such as etoposide, ifosfamide, cisplatin, bleomycin sulfate, gemicitabine, carboplatin and oxaliplatin. ZIOPHARM Oncology Inc. is the only company with a molecule in the clinical pipeline for testicular cancer therapeutics. Very few companies are investing in R&D for testicular cancer.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the testicular cancer therapeutics market.
- Analysis of key recent licensing and partnership agreements in testicular cancer therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global testicular cancer market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global testicular cancer market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global testicular cancer market landscape? - Identify, understand and capitalize.
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 INTRODUCTION
2.1 Overview
2.1.1 Histological Classification of Testicular Tumors Based on WHO
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.4 Risk Factors
2.5 Signs and Symptoms
2.6 Diagnosis
2.6.1 Physical Examination and History
2.6.2 Biopsy
2.6.3 Blood Test
2.6.4 Imaging Techniques
2.7 Staging
2.7.1 Testicular Cancer can be Categorized as Being in one of These Stages
2.7.2 Recurrent Testicular Cancer:
2.8 Survival Rate by Stage
2.9 Treatment and Management Pattern
2.9.1 Three Types of Standard Treatment are used:
2.9.2 Management of CIS and Germ Cell Tumors
2.9.3 Treatment Options by Stage
2.9.4 Chemotherapy Regimens
2.10 GlobalData Pipeline Report Guidance
3 TESTICULAR CANCER THERAPEUTICS: MARKET CHARACTERIZATION
3.1 Testicular Cancer Therapeutics Market Size (2005-2010) – Global
3.2 Testicular Cancer Therapeutics Market Forecast (2010-2017) – Global
3.3 Testicular Cancer Therapeutics Market Size (2005-2010) – The US
3.4 Testicular Cancer Therapeutics Market Forecast (2010-2017) – The US
3.5 Testicular Cancer Therapeutics Market Size (2005-2010) – France
3.6 Testicular Cancer Therapeutics Market Forecast (2010-2017) – France
3.7 Testicular Cancer Therapeutics Market Size (2005-2010) – Germany
3.8 Testicular Cancer Therapeutics Market Forecast (2010-2017) – Germany
3.9 Testicular Cancer Therapeutics Market Size (2005-2010) – Italy
3.10 Testicular Cancer Therapeutics Market Forecast (2010-2017) – Italy
3.11 Testicular Cancer Therapeutics Market Size (2005-2010) – Spain
3.12 Testicular Cancer Therapeutics Market Forecast (2010-2017) – Spain
3.13 Testicular Cancer Therapeutics Market Size (2005-2010) – The UK
3.14 Testicular Cancer Therapeutics Market Forecast (2010-2017) – The UK
3.15 Testicular Cancer Therapeutics Market Size (2005-2010) – Japan
3.16 Testicular Cancer Therapeutics Market Forecast (2010-2017) – Japan
3.17 Drivers and Restraints for the Testicular Cancer Therapeutics Market
3.17.1 Drivers of the Testicular Cancer Therapeutics Market
3.17.2 Barriers for the Testicular Cancer Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 TESTICULAR CANCER THERAPEUTICS: COMPETITIVE ASSESSMENT
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.2 Major Marketed Product Profiles in the Testicular Cancer Therapeutics Market
4.2.1 Drugs Acting by Influencing Structure and Function of Deoxyribo Nucleic Acid (DNA)
4.2.2 Drugs Acting by Interfering with Microtubule Assembly
4.2.3 Drugs Acting by Inhibiting Biosynthesis of Nucleic Acids
4.3 Key Takeaway
5 TESTICULAR CANCER THERAPEUTICS: PIPELINE ASSESSMENT
5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 Technology Trends Analytic Framework
5.3 Testicular Cancer Therapeutics Pipeline Analysis – Pipeline by Clinical Phases of Development
5.3.1 Testicular Cancer Therapeutics – Phase II Clinical Pipeline
5.3.2 Testicular Cancer Therapeutics – Phase I Clinical Pipeline
5.4 Testicular Cancer Therapeutics Pipeline by Mechanism of Action
5.5 Testicular Cancer Therapeutics Technology Trends Analytical Framework
5.6 Testicular Cancer Therapeutics Pipeline by Monotherapy and Combination Therapy
5.7 Testicular Cancer Therapeutics – Promising Drugs under Clinical Development
5.8 Key Takeaway
6 TESTICULAR CANCER THERAPEUTICS:CLINICAL TRIALS MAPPING
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Therapeutics Clinical Trials
7 TESTICULAR CANCER THERAPEUTICS: STRATEGIC ASSESSMENT
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 GLOBAL TESTICULAR CANCER THERAPEUTICS MARKET: FUTURE PLAYERS
8.1 Introduction
8.2 ZIOPHARM Oncology, Inc
8.2.1 Company Overview
8.2.2 Financial Overview
8.2.3 Business Overview
8.2.4 Oncology Pipeline
8.2.5 Testicular Cancer Therapeutics Pipeline
8.2.6 Deals, Alliance and Partnerships
9 GLOBAL TESTICULAR CANCER THERAPEUTICS MARKET: APPENDIX
9.1 Definitions
9.2 Acronyms
9.3 Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Forecasting
9.3.4 Primary Research
9.3.5 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Bibliography
LIST OF TABLES
Table 1: Classification of Tumours Based on How Well the Tumours are Expected to Respond to Treatment
Table 2: Testicular Cancer Chemotherapy Regimens
Table 3: Testicular Cancer Therapeutics Market, Global, Revenue ($m), 2005–2010
Table 4: Testicular Cancer Therapeutics Market, Global, Forecast ($m), 2010–2017
Table 5: Testicular Cancer Therapeutics Market, the US, Revenue ($m), 2005–2010
Table 6: Testicular Cancer Therapeutics Market, the US, Forecasts ($m), 2010–2017
Table 7: Testicular Cancer Therapeutics, France, Revenue ($m), 2005–2010
Table 8: Testicular Cancer Therapeutics Market, France, Forecasts ($m), 2010–2017
Table 9: Testicular Cancer Therapeutics, Germany, Revenue ($m), 2005–2010
Table 10: Testicular Cancer Therapeutics Market, Germany, Forecasts ($m), 2010–2017
Table 11: Testicular Cancer Therapeutics, Italy, Revenue ($m), 2005–2010
Table 12: Testicular Cancer Therapeutics Market, Italy, Forecasts ($m), 2010–2017
Table 13: Testicular Cancer Therapeutics, Spain, Revenue ($m), 2005–2010
Table 14: Testicular Cancer Therapeutics Market, Spain, Forecasts ($m), 2010–2017
Table 15: Testicular Cancer Therapeutics Market, the UK, Revenue ($m), 2005–2010
Table 16: Testicular Cancer Therapeutics Market, the UK, Forecasts ($m), 2010–2017
Table 17: Testicular Cancer Therapeutics Market, Japan, Revenue ($m), 2005–2010
Table 18: Testicular Cancer Therapeutics Market, Japan, Forecasts ($m), 2010–2017
Table 19: Testicular Cancer Therapeutics – Phase II Clinical Pipeline, 2011
Table 20: Testicular Cancer Therapeutics – Phase I Clinical Pipeline, 2011
Table 21: Testicular Cancer Therapeutics, Global, Clinical Trials by Country, 2011
Table 22: Testicular Cancer Therapeutics, Global, Clinical Trials by Phase, 2011
Table 23: Testicular Cancer Therapeutics, Global, Clinical Trials by Status of Development, 2011
Table 24: Testicular Cancer Therapeutics, Prominent Sponsors, 2011
Table 25: Testicular Cancer Therapeutics, Clinical Trials of Companies by Phase, 2011
Table 26: ZIOPHARM Oncology Inc – Oncology Pipeline, 2011
Table 27: ZIOPHARM Oncology Inc – Molecules in Pipeline for Testicular Cancer, 2011
Table 28: ZIOPHARM Oncology Inc., Deals
LIST OF FIGURES
Figure 1: Treatment of Testicular Cancer by Stage
Figure 2: Treatment of Testicular Cancer by Stage
Figure 3: Testicular Cancer by Stage
Figure 4: Stages of Testicular Cancer
Figure 5: Testicular Cancer Therapeutics Market, Global, Revenue ($m), 2005–2010
Figure 6: Testicular Cancer Therapeutics Market, Global, Forecast ($m), 2010–2017
Figure 7: Testicular Cancer Therapeutics Market, the US, Revenue ($m), 2005–2010
Figure 8: Testicular Cancer Therapeutics Market, the US, Forecast ($m), 2010–2017
Figure 9: Testicular Cancer Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 10: Testicular Cancer Therapeutics Market, France, Forecast ($m), 2010–2017
Figure 11: Testicular Cancer Therapeutics Market, Germany, Revenue ($m), 2005–2010
Figure 12: Testicular Cancer Therapeutics Market, Germany, Forecast ($m), 2010–2017
Figure 13: Testicular Cancer Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 14: Testicular Cancer Therapeutics Market, Italy, Forecast ($m), 2010–2017
Figure 15: Testicular Cancer Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 16: Testicular Cancer Therapeutics Market, Spain, Forecast ($m), 2010–2017
Figure 17: Testicular Cancer Therapeutics Market, the UK, Revenue ($m), 2005–2010
Figure 18: Testicular Cancer Therapeutics Market, the UK, Forecast ($m), 2010–2017
Figure 19: Testicular Cancer Therapeutics Market, Japan, Revenue ($m), 2005–2010
Figure 20: Testicular Cancer Therapeutics Market, Japan, Forecast ($m), 2010–2017
Figure 21: Opportunity and Unmet Need in the Testicular Cancer Therapeutics Market, 2011
Figure 22: Strategic Competitor Assessment of the Major Marketed Products in Testicular Cancer, 2011
Figure 23: Testicular Cancer Pipeline Products by Phase of Clinical Development, 2011
Figure 24: Testicular Cancer Pipeline by Clinical Phases of Development
Figure 25: Testicular Cancer Therapeutics – Pipeline by Mechanism of Action (%), 2011
Figure 26: Technology Trends Analytical Framework for the Testicular Cancer Therapeutics Pipeline, 2011
Figure 27: Technology Trends Analytical Framework for the Testicular Cancer Therapeutics Pipeline, 2011
Figure 28: Testicular Cancer Pipeline Products by Monotherapy and Combination Therapy, 2011
Figure 29: Testicular Cancer Therapeutics – Clinical Trials by Country, 2011
Figure 30: Testicular Cancer Therapeutics, Major Markets – Clinical Trials by Phase, 2011
Figure 31: Testicular Cancer Therapeutics, Major Markets, Clinical Trials by Development Status, 2011
Figure 32: Testicular Cancer Therapeutics, Major Markets, Prominent Sponsors, 2011
Figure 33: Testicular Cancer Therapeutics, Prominent Sponsors, 2011
Figure 34: Testicular Cancer Therapeutics, Major Markets, Clinical Trials of Companies by Phase, 2011
Figure 35: Testicular Cancer Therapeutics Market, Drivers and Restraints, 2011
Figure 36: Implications for Future Market Competition in the Testicular Cancer Therapeutics Market, 2011
Figure 37: Testicular Cancer Therapeutics, Clinical Pipeline by Company, 2011
Figure 38: GlobalData Market Forecasting Model
COMPANIES MENTIONED
ZIOPHARM Oncology, Inc
1.1 List of Tables
1.2 List of Figures
2 INTRODUCTION
2.1 Overview
2.1.1 Histological Classification of Testicular Tumors Based on WHO
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.4 Risk Factors
2.5 Signs and Symptoms
2.6 Diagnosis
2.6.1 Physical Examination and History
2.6.2 Biopsy
2.6.3 Blood Test
2.6.4 Imaging Techniques
2.7 Staging
2.7.1 Testicular Cancer can be Categorized as Being in one of These Stages
2.7.2 Recurrent Testicular Cancer:
2.8 Survival Rate by Stage
2.9 Treatment and Management Pattern
2.9.1 Three Types of Standard Treatment are used:
2.9.2 Management of CIS and Germ Cell Tumors
2.9.3 Treatment Options by Stage
2.9.4 Chemotherapy Regimens
2.10 GlobalData Pipeline Report Guidance
3 TESTICULAR CANCER THERAPEUTICS: MARKET CHARACTERIZATION
3.1 Testicular Cancer Therapeutics Market Size (2005-2010) – Global
3.2 Testicular Cancer Therapeutics Market Forecast (2010-2017) – Global
3.3 Testicular Cancer Therapeutics Market Size (2005-2010) – The US
3.4 Testicular Cancer Therapeutics Market Forecast (2010-2017) – The US
3.5 Testicular Cancer Therapeutics Market Size (2005-2010) – France
3.6 Testicular Cancer Therapeutics Market Forecast (2010-2017) – France
3.7 Testicular Cancer Therapeutics Market Size (2005-2010) – Germany
3.8 Testicular Cancer Therapeutics Market Forecast (2010-2017) – Germany
3.9 Testicular Cancer Therapeutics Market Size (2005-2010) – Italy
3.10 Testicular Cancer Therapeutics Market Forecast (2010-2017) – Italy
3.11 Testicular Cancer Therapeutics Market Size (2005-2010) – Spain
3.12 Testicular Cancer Therapeutics Market Forecast (2010-2017) – Spain
3.13 Testicular Cancer Therapeutics Market Size (2005-2010) – The UK
3.14 Testicular Cancer Therapeutics Market Forecast (2010-2017) – The UK
3.15 Testicular Cancer Therapeutics Market Size (2005-2010) – Japan
3.16 Testicular Cancer Therapeutics Market Forecast (2010-2017) – Japan
3.17 Drivers and Restraints for the Testicular Cancer Therapeutics Market
3.17.1 Drivers of the Testicular Cancer Therapeutics Market
3.17.2 Barriers for the Testicular Cancer Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 TESTICULAR CANCER THERAPEUTICS: COMPETITIVE ASSESSMENT
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.2 Major Marketed Product Profiles in the Testicular Cancer Therapeutics Market
4.2.1 Drugs Acting by Influencing Structure and Function of Deoxyribo Nucleic Acid (DNA)
4.2.2 Drugs Acting by Interfering with Microtubule Assembly
4.2.3 Drugs Acting by Inhibiting Biosynthesis of Nucleic Acids
4.3 Key Takeaway
5 TESTICULAR CANCER THERAPEUTICS: PIPELINE ASSESSMENT
5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 Technology Trends Analytic Framework
5.3 Testicular Cancer Therapeutics Pipeline Analysis – Pipeline by Clinical Phases of Development
5.3.1 Testicular Cancer Therapeutics – Phase II Clinical Pipeline
5.3.2 Testicular Cancer Therapeutics – Phase I Clinical Pipeline
5.4 Testicular Cancer Therapeutics Pipeline by Mechanism of Action
5.5 Testicular Cancer Therapeutics Technology Trends Analytical Framework
5.6 Testicular Cancer Therapeutics Pipeline by Monotherapy and Combination Therapy
5.7 Testicular Cancer Therapeutics – Promising Drugs under Clinical Development
5.8 Key Takeaway
6 TESTICULAR CANCER THERAPEUTICS:CLINICAL TRIALS MAPPING
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Therapeutics Clinical Trials
7 TESTICULAR CANCER THERAPEUTICS: STRATEGIC ASSESSMENT
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 GLOBAL TESTICULAR CANCER THERAPEUTICS MARKET: FUTURE PLAYERS
8.1 Introduction
8.2 ZIOPHARM Oncology, Inc
8.2.1 Company Overview
8.2.2 Financial Overview
8.2.3 Business Overview
8.2.4 Oncology Pipeline
8.2.5 Testicular Cancer Therapeutics Pipeline
8.2.6 Deals, Alliance and Partnerships
9 GLOBAL TESTICULAR CANCER THERAPEUTICS MARKET: APPENDIX
9.1 Definitions
9.2 Acronyms
9.3 Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Forecasting
9.3.4 Primary Research
9.3.5 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Bibliography
LIST OF TABLES
Table 1: Classification of Tumours Based on How Well the Tumours are Expected to Respond to Treatment
Table 2: Testicular Cancer Chemotherapy Regimens
Table 3: Testicular Cancer Therapeutics Market, Global, Revenue ($m), 2005–2010
Table 4: Testicular Cancer Therapeutics Market, Global, Forecast ($m), 2010–2017
Table 5: Testicular Cancer Therapeutics Market, the US, Revenue ($m), 2005–2010
Table 6: Testicular Cancer Therapeutics Market, the US, Forecasts ($m), 2010–2017
Table 7: Testicular Cancer Therapeutics, France, Revenue ($m), 2005–2010
Table 8: Testicular Cancer Therapeutics Market, France, Forecasts ($m), 2010–2017
Table 9: Testicular Cancer Therapeutics, Germany, Revenue ($m), 2005–2010
Table 10: Testicular Cancer Therapeutics Market, Germany, Forecasts ($m), 2010–2017
Table 11: Testicular Cancer Therapeutics, Italy, Revenue ($m), 2005–2010
Table 12: Testicular Cancer Therapeutics Market, Italy, Forecasts ($m), 2010–2017
Table 13: Testicular Cancer Therapeutics, Spain, Revenue ($m), 2005–2010
Table 14: Testicular Cancer Therapeutics Market, Spain, Forecasts ($m), 2010–2017
Table 15: Testicular Cancer Therapeutics Market, the UK, Revenue ($m), 2005–2010
Table 16: Testicular Cancer Therapeutics Market, the UK, Forecasts ($m), 2010–2017
Table 17: Testicular Cancer Therapeutics Market, Japan, Revenue ($m), 2005–2010
Table 18: Testicular Cancer Therapeutics Market, Japan, Forecasts ($m), 2010–2017
Table 19: Testicular Cancer Therapeutics – Phase II Clinical Pipeline, 2011
Table 20: Testicular Cancer Therapeutics – Phase I Clinical Pipeline, 2011
Table 21: Testicular Cancer Therapeutics, Global, Clinical Trials by Country, 2011
Table 22: Testicular Cancer Therapeutics, Global, Clinical Trials by Phase, 2011
Table 23: Testicular Cancer Therapeutics, Global, Clinical Trials by Status of Development, 2011
Table 24: Testicular Cancer Therapeutics, Prominent Sponsors, 2011
Table 25: Testicular Cancer Therapeutics, Clinical Trials of Companies by Phase, 2011
Table 26: ZIOPHARM Oncology Inc – Oncology Pipeline, 2011
Table 27: ZIOPHARM Oncology Inc – Molecules in Pipeline for Testicular Cancer, 2011
Table 28: ZIOPHARM Oncology Inc., Deals
LIST OF FIGURES
Figure 1: Treatment of Testicular Cancer by Stage
Figure 2: Treatment of Testicular Cancer by Stage
Figure 3: Testicular Cancer by Stage
Figure 4: Stages of Testicular Cancer
Figure 5: Testicular Cancer Therapeutics Market, Global, Revenue ($m), 2005–2010
Figure 6: Testicular Cancer Therapeutics Market, Global, Forecast ($m), 2010–2017
Figure 7: Testicular Cancer Therapeutics Market, the US, Revenue ($m), 2005–2010
Figure 8: Testicular Cancer Therapeutics Market, the US, Forecast ($m), 2010–2017
Figure 9: Testicular Cancer Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 10: Testicular Cancer Therapeutics Market, France, Forecast ($m), 2010–2017
Figure 11: Testicular Cancer Therapeutics Market, Germany, Revenue ($m), 2005–2010
Figure 12: Testicular Cancer Therapeutics Market, Germany, Forecast ($m), 2010–2017
Figure 13: Testicular Cancer Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 14: Testicular Cancer Therapeutics Market, Italy, Forecast ($m), 2010–2017
Figure 15: Testicular Cancer Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 16: Testicular Cancer Therapeutics Market, Spain, Forecast ($m), 2010–2017
Figure 17: Testicular Cancer Therapeutics Market, the UK, Revenue ($m), 2005–2010
Figure 18: Testicular Cancer Therapeutics Market, the UK, Forecast ($m), 2010–2017
Figure 19: Testicular Cancer Therapeutics Market, Japan, Revenue ($m), 2005–2010
Figure 20: Testicular Cancer Therapeutics Market, Japan, Forecast ($m), 2010–2017
Figure 21: Opportunity and Unmet Need in the Testicular Cancer Therapeutics Market, 2011
Figure 22: Strategic Competitor Assessment of the Major Marketed Products in Testicular Cancer, 2011
Figure 23: Testicular Cancer Pipeline Products by Phase of Clinical Development, 2011
Figure 24: Testicular Cancer Pipeline by Clinical Phases of Development
Figure 25: Testicular Cancer Therapeutics – Pipeline by Mechanism of Action (%), 2011
Figure 26: Technology Trends Analytical Framework for the Testicular Cancer Therapeutics Pipeline, 2011
Figure 27: Technology Trends Analytical Framework for the Testicular Cancer Therapeutics Pipeline, 2011
Figure 28: Testicular Cancer Pipeline Products by Monotherapy and Combination Therapy, 2011
Figure 29: Testicular Cancer Therapeutics – Clinical Trials by Country, 2011
Figure 30: Testicular Cancer Therapeutics, Major Markets – Clinical Trials by Phase, 2011
Figure 31: Testicular Cancer Therapeutics, Major Markets, Clinical Trials by Development Status, 2011
Figure 32: Testicular Cancer Therapeutics, Major Markets, Prominent Sponsors, 2011
Figure 33: Testicular Cancer Therapeutics, Prominent Sponsors, 2011
Figure 34: Testicular Cancer Therapeutics, Major Markets, Clinical Trials of Companies by Phase, 2011
Figure 35: Testicular Cancer Therapeutics Market, Drivers and Restraints, 2011
Figure 36: Implications for Future Market Competition in the Testicular Cancer Therapeutics Market, 2011
Figure 37: Testicular Cancer Therapeutics, Clinical Pipeline by Company, 2011
Figure 38: GlobalData Market Forecasting Model
COMPANIES MENTIONED
ZIOPHARM Oncology, Inc
